Ingrid Øra

Dr. Ingrid Øra

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2012 in Nature
Verified
Journal Article
Open access
JMJan J. Molenaar
Jan J. Molenaar
JKJan Koster
Jan Koster
DZDanny A. Zwijnenburg
Danny A. Zwijnenburg
PSPeter van Sluis
Peter van Sluis
LVLinda J. Valentijn
Linda J. Valentijn
RVRogier Versteeg
Rogier Versteeg
Neuroblastoma is a childhood tumour of the peripheral sympathetic nervous system. The pathogenesis has for a long time been quite enigmatic, as only very few gene defects were identified in this often lethal tumour. Frequently detected gene alterations are limited to MYCN amplification (20%) and ALK activations (7%). Here we present a whole-genome sequence analysis of 87 neuroblastoma of all stages. Few recurrent amino-acid-changing mutations were found. In contrast, analysis of structural defects identified a local shredding of chromosomes, known as chromothripsis, in 18% of high-stage neuroblastoma. These tumours are associated with a poor outcome. Structural alterations recurrently affected ODZ3, PTPRD and CSMD1, which are involved in neuronal growth cone stabilization. In addition, ATRX, TIAM1 and a series of regulators of the Rac/Rho pathway were mutated, further implicating defects in neuritogenesis in neuroblastoma. Most tumours with defects in these genes were aggressive high-stage neuroblastomas, but did not carry MYCN amplifications. The genomic landscape of neuroblastoma therefore reveals two novel molecular defects, chromothripsis and neuritogenesis gene alterations, which frequently occur in high-risk tumours.

1 March 2009 in Cancer Research
Verified
Journal Article
Closed access
PDF file
JSJohannes H Schulte
Johannes H Schulte
SLSoyoung Lim
Soyoung Lim
Alexander SchrammAlexander Schramm
Alexander Schramm
NFNicolaus Friedrichs
Nicolaus Friedrichs
JKJan Koster
Jan Koster
JKJutta Kirfel
Jutta Kirfel
Aberrant epigenetic changes in DNA methylation and histone acetylation are hallmarks of most cancers, whereas histone methylation was previously considered to be irreversible and less versatile. Recently, several histone demethylases were identified catalyzing the removal of methyl groups from histone H3 lysine residues and thereby influencing gene expression. Neuroblastomas continue to remain a clinical challenge despite advances in multimodal therapy. Here, we address the functional significance of the chromatin-modifying enzyme lysine-specific demethylase 1 (LSD1) in neuroblastoma. LSD1 expression correlated with adverse outcome and was inversely correlated with differentiation in neuroblastic tumors. Differentiation of neuroblastoma cells resulted in down-regulation of LSD1. Small interfering RNA–mediated knockdown of LSD1 decreased cellular growth, induced expression of differentiation-associated genes, and increased target gene–specific H3K4 methylation. Moreover, LSD1 inhibition using monoamine oxidase inhibitors resulted in an increase of global H3K4 methylation and growth inhibition of neuroblastoma cells in vitro. Finally, targeting LSD1 reduced neuroblastoma xenograft growth in vivo. Here, we provide the first evidence that a histone demethylase, LSD1, is involved in maintaining the undifferentiated, malignant phenotype of neuroblastoma cells. We show that inhibition of LSD1 reprograms the transcriptome of neuroblastoma cells and inhibits neuroblastoma xenograft growth. Our results suggest that targeting histone demethylases may provide a novel option for cancer therapy. [Cancer Res 2009;69(5):2065–71]

14 May 2002 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
AJAnnika Jögi
Annika Jögi
IØIngrid Øra
Ingrid Øra
HNHelén Nilsson
Helén Nilsson
ÅLÅsa Lindeheim
Åsa Lindeheim
YMYuichi Makino
Yuichi Makino
SPSven Påhlman
Sven Påhlman
Insufficient oxygen and nutrient supply often restrain solid tumor growth, and the hypoxia-inducible factors (HIF) 1α and HIF-2α are key transcription regulators of phenotypic adaptation to low oxygen levels. Moreover, mouse gene disruption studies have implicated HIF-2 α in embryonic regulation of tyrosine hydroxylase , a hallmark gene of the sympathetic nervous system. Neuroblastoma tumors originate from immature sympathetic cells, and therefore we investigated the effect of hypoxia on the differentiation status of human neuroblastoma cells. Hypoxia stabilized HIF-1α and HIF-2α proteins and activated the expression of known hypoxia-induced genes, such as vascular endothelial growth factor and tyrosine hydroxylase . These changes in gene expression also occurred in hypoxic regions of experimental neuroblastoma xenografts grown in mice. In contrast, hypoxia decreased the expression of several neuronal/neuroendocrine marker genes but induced genes expressed in neural crest sympathetic progenitors, for instance c-kit and Notch-1 . Thus, hypoxia apparently causes dedifferentiation both in vitro and in vivo . These findings suggest a novel mechanism for selection of highly malignant tumor cells with stem-cell characteristics.

1 July 2010 in Cell
Verified
Journal Article
Closed access
MHMichael Hölzel
Michael Hölzel
SHSidong Huang
Sidong Huang
JKJan Koster
Jan Koster
IØIngrid Øra
Ingrid Øra
ALArjan Lakeman
Arjan Lakeman
RBRené Bernards
René Bernards

29 January 2014 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
CWCharles Walther
Charles Walther
JTJohnbosco Tayebwa
Johnbosco Tayebwa
HLHenrik Lilljebjörn
Henrik Lilljebjörn
LMLinda Magnusson
Linda Magnusson
JNJenny Nilsson
Jenny Nilsson
FMFredrik Mertens
Fredrik Mertens

11 December 2007 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
APAlexander Pietras
Alexander Pietras
DGD Gisselsson
D Gisselsson
IØIngrid Øra
Ingrid Øra
RNR Noguera
R Noguera
SBS Beckman
S Beckman
SPS Påhlman
S Påhlman